A detailed history of Brevan Howard Capital Management LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 79,468 shares of BCRX stock, worth $561,044. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79,468
Previous 94,467 15.88%
Holding current value
$561,044
Previous $583,000 3.43%
% of portfolio
0.0%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.41 - $8.69 $96,143 - $130,341
-14,999 Reduced 15.88%
79,468 $603,000
Q2 2024

Aug 14, 2024

BUY
$4.13 - $6.79 $338,527 - $556,562
81,968 Added 655.8%
94,467 $583,000
Q1 2024

May 15, 2024

SELL
$4.89 - $7.65 $281,624 - $440,578
-57,592 Reduced 82.17%
12,499 $63,000
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $349,053 - $474,516
70,091 New
70,091 $419,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.31B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Brevan Howard Capital Management LP Portfolio

Follow Brevan Howard Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brevan Howard Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Brevan Howard Capital Management LP with notifications on news.